undamentalytics Newsletter
Sign in

Bioaffinity Technologies, Inc. balance sheet

At the end of fiscal 2025, Bioaffinity Technologies, Inc. had total assets of $11.0m, total liabilities of $3.7m and shareholders' equity of $7.3m. It held $6.4m in cash against $146,474 of debt: net cash of $6.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents113162
Receivables01111
Inventory00000
Total current assets124384
Goodwill—1111
Total assets1287118
Accounts payable01111
Deferred revenue (current)—0000
Total current liabilities12333
Long-term debt——000
Total debt00000
Total liabilities13444
Shareholders' equity115374
Net debt (negative = net cash)−11−3−1−6−2
Shares outstanding————7m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BIAF vs LUCDBIAF vs NRXSBIAF vs MCTA

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bioaffinity Technologies, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bioaffinity Technologies, Inc.